- Home
- PSTV vs QLGN Comparison
PSTV vs QLGN Comparison
Compare PSTV & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- QLGN
- Stock Information
- Founded
- PSTV 1996
- QLGN 1996
- Country
- PSTV United States
- QLGN United States
- Employees
- PSTV N/A
- QLGN N/A
- Industry
- PSTV Medical/Dental Instruments
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- PSTV Health Care
- QLGN Health Care
- Exchange
- PSTV Nasdaq
- QLGN Nasdaq
- Market Cap
- PSTV 2.1M
- QLGN 2.4M
- IPO Year
- PSTV N/A
- QLGN N/A
- Fundamental
- Price
- PSTV $0.79
- QLGN $3.21
- Analyst Decision
- PSTV Strong Buy
- QLGN
- Analyst Count
- PSTV 3
- QLGN 0
- Target Price
- PSTV $11.17
- QLGN N/A
- AVG Volume (30 Days)
- PSTV 30.3M
- QLGN 116.9K
- Earning Date
- PSTV 03-27-2025
- QLGN 04-15-2025
- Dividend Yield
- PSTV N/A
- QLGN N/A
- EPS Growth
- PSTV N/A
- QLGN N/A
- EPS
- PSTV N/A
- QLGN N/A
- Revenue
- PSTV $5,824,000.00
- QLGN N/A
- Revenue This Year
- PSTV N/A
- QLGN N/A
- Revenue Next Year
- PSTV N/A
- QLGN N/A
- P/E Ratio
- PSTV N/A
- QLGN N/A
- Revenue Growth
- PSTV 18.54
- QLGN N/A
- 52 Week Low
- PSTV $0.24
- QLGN $2.96
- 52 Week High
- PSTV $2.67
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- PSTV 45.78
- QLGN 39.04
- Support Level
- PSTV $0.75
- QLGN $3.06
- Resistance Level
- PSTV $1.77
- QLGN $3.78
- Average True Range (ATR)
- PSTV 0.31
- QLGN 0.29
- MACD
- PSTV -0.03
- QLGN -0.00
- Stochastic Oscillator
- PSTV 22.64
- QLGN 1.12
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.